Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence

British Journal of Haematology
Kirsten Bleckmann, Martin Schrappe

Abstract

The presence of the BCR/ABL1 fusion gene in childhood acute lymphoblastic leukaemia (ALL) is a rare finding and has been an adverse prognostic factor associated with a high risk of therapeutic failure. The current key components of treatment are intensive polychemotherapy and a BCR/ABL1 kinase domain inhibitor. This treatment approach has been applied in a few clinical trials by paediatric leukaemia study groups. Thus, this subtype of ALL serves as the first model system for truly targeted treatment. The role of haematopoietic stem cell transplantation (HSCT) is increasingly called into question, at least in a favourable, though not yet clearly defined, subset of patients. Currently, the choice of the most effective tyrosine kinase inhibitor is not yet settled, in particular, in view of potential reduction of overall treatment intensity.

References

Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D I MarksA Oakhill
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianE J Freireich
Apr 6, 2000·The New England Journal of Medicine·M AricòG Masera
Jul 15, 2004·Blood·Ching-Hon PuiUNKNOWN Total Therapy Study XIIIB at St Jude Children's Research Hospital
Jan 13, 2006·The New England Journal of Medicine·Ching-Hon Pui, William E Evans
May 12, 2006·The New England Journal of Medicine·Ellin BermanNicholas P Sauter
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
May 9, 2008·Leukemia & Lymphoma·Charles Mullighan, James Downing
Jun 14, 2008·Expert Opinion on Investigational Drugs·Elias JabbourHagop Kantarjian
Jul 9, 2009·Current Opinion in Oncology·Oliver G Ottmann, Heike Pfeifer
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giovanni MartinelliRobin Foà
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirk R SchultzBruce Camitta
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato BassanAlessandro Rambaldi
Sep 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurizio AricòMaria Grazia Valsecchi

❮ Previous
Next ❯

Citations

Nov 4, 2017·F1000Research·Jan Starý, Ondřej Hrušák
Aug 12, 2020·Pediatric Blood & Cancer·William B SlaytonStephen P Hunger
Dec 27, 2016·Frontiers in Pharmacology·Stefania TrinoPellegrino Musto
Mar 31, 2021·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·Víctor Galán GómezAntonio Pérez-Martínez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.